. >>> amgen wins a patent lawsuit decision against regeneron pharmaceuticals. a new kind of cholesterol lowering drug that was dropped. regeneron also a little higher 368.46 the close there. >>> cesars entertainment and private equity owners could be facing up to $5 billion in potential damages after a court examiner said a series of corporate deals led to this casino company's operating unit filing for bankruptcy. the bankruptcy court had been looking into whether the company and its backers stripped away assets leaving the unit unable to pay debts. shares were down more than 13% to $6.23. >>> apple has responded yet again to the fbi with a court filing last night. further entrenching itself in the privacy battle against the government. the tech company claims that the fbi has not exhausted all options to unlock the phone used by one of the allege ed fro ed terrorists in the san bernardino attacks last year and will not develop a back door into its mobile operating system. shares of apple rose. >>> retailer william sonoma reporting weaker than expected fourth

one pressure ongoing is an ginseng regeneron's drug restricts upon his own. cause the stop to go down. one that already slid by about 40% from last year's peak. >> you mentioned apple and regeneron obviously having an impact. any week percentage movers that caught your attention? >> lululemon shares are soaring top estimates in a strong holiday season despite a mixed outlook going forward. worth noting a stock -- carol: thank you, abigail. , wiped out any gains for the week. janet yellen's comments yesterday. the chief investment officer of fixed income was on bloomberg tv earlier today. he claimed why this was so crucial for the -- for the fed as well as central banks. fed butust the everybody, first of all, get your currencies weaker. that is basically what they're trying to do and so far what we have seen in the recent time frames, the ecb and the boj have not been successful in doing that. yesterday's announcement and the previous more dovish fed, the dollar has weakened off the highs. that is a positive because i do not think the fed wants the dollar to

the second-best performer was easily gettable, regeneron. the ceo was our first guest on "mad money." and he told us regeneron had developed a medicine that could stabilize macular degeneration, a disease that causes blindness. the catch? he said you had to inject it into your eyes 12 times a year. that's hardly an inviting prospect, right? prese prese when i pressed him on why anyone would do that, he said the current regimen is once a week. so i told you regereron as buy buy buy! i like the third best performer under armour since my daughter's field hockey team adopted the clothing line. my eyes didn't lie. 2,482% gain. gettable. because i saw what my daughter was wearing and did the homework. we've had ceo kevin plank on for years and we've recommended you buy every tip. this recent pull-back no different. under armour's a technology company that happens to sell clothes. wyndham worldwide, up 2,288%. i think that was within the realm of opportunity. if you had listened when ceo steve holmes came on the show repeatedly wyndham went from be

apparel winner mock and we're up closer to 15% and you have a stock like regeneron pharmaceuticals, up 3,000 property and general growth properties, the mall operator, the mall proner, that real estate investment trust. "moulin rouge"ly beat enup in the crisis and those are at 10% aren't among the current s&p 500 members, as for the lag yard line in surprise i guess, it's will the palincks, those stocks have at all ben by two-thirds or $1/4 of their value and how much they are down during that time span as well. leaders and lag yards, i guess it all depends, at least for the celebration, about what you were long and what you were short during this period of type. we know the overhaul market was up but some stocks have really lagged behind. back over to you guys. >> thanks so much, dom. dom had a bottle of champagne. >> is he by himself? >> he's in the newsroom right now. >> i hope he stairs with us. >> let's -- in terms of some of the liters of the bull mark, constructioner deschristian knee and i reept to romy a high growth high investment period like we've never seen before and you w

regeneron is still halted. out over the next 12 to 18 months so could be a long process. >> back to you. >> thank you so much. european markets are closing right now. simon hobbs at the new york stock exchange has a look. simon. >> hey, scott, markets are lower in advance of a fed decision in 90 minutes time. the banks are a key focus. the ceo said that challenges conditions persist for ubs and no recovery there in wealth management or investment banking and they suggested a small loss for the year. the u.k. finance minister delivered his annual budget in which he said that multinationals like google will pay more tax moving forward but the headline coming out is going to put a sugar tax on sodas. we'll see if that's replicated around the world. the housing stocks are are higher. george osborne suggesting that they will accelerate the move into affordable housing. you have also seen during the course of the session that the oil and gas stocks are moving higher as well as he effectively aboll ishes the revenue l

. >>> regeneron opening for trading, down half a percent. the stock was halted ahead of a jury verdict. the jury decided against both sanofe and regeneron. they plan to appeal the verdict. they were up 2%, 2.5% before the halt happened at 11:44. shares now down as well. sanofi and amgen as well. >>> house speaker paul ryan sounding off on the 2016 election to john harwood. hear what he has to say. >>> and we're counting you down to the fed's latest decision on interest rates, right at 2:00 p.m. eastern time. we're seeing big moves in the market ahead of the fed. the dollar is hitting highs of the day. "power lunch" will be right back. (son) pa, i know we settle for cable... but directv has been number one in customer satisfaction over cable for 15 years. (father) how 'bout over 15 satisfying years with that woman over there boiling your clothes. her layers and layers of...layers. hair that i've rarely seen because it's always under that bonnet. and how she fought off that grizzly and made him into these slippers. that's satisfaction son. (vo

regeneron's a good example of a company that had enormous sales growth. look at this, $446 million in 2011 and now you're dealing with $4 billion. that's enormous, but it slows down. the numbers slow down eventually, because you get so big, you hit the law of large numbers. and of course, that's fueled the stock price. remember, regeneron was $30 or $40 ages and ages ago, and it was $40, $50 in 2011? and it went all the way to $500 or so in the beginning of january. since then, you see it's come down. but there's been a straight-up rocket all the way into the end of 2015 overall. so, we'll talk a little bit more about whether or not you want to buy biotech or whether you should move into smaller cap biotech a little later on in the day. i finally wanted to note for the quarter, the big winner, of course, is a lot of the names that are anywhere in the materials group. but spider gold trust, look, up 16% year-to-date. i understand this is the biggest quarterly rise in 15 years for gold. i'm trying to confirm that. certainly a tremendous quarter for these pe

relative selling, we're talking about the big names, amgen, regeneron, alexi.e does not seem to be in a new fundamental news. i reached out to our biotech analyst, who said that he saw after a couple of good days, or could be some retalix -- there could be some reflex volatility. sure that the biotech bear market is over. we could see more selling ahead. >> thank you. fascinating. securities and exchange commission still has a number of regulations and projects in the works, but aim to boost stability and enhance the overall structure of equity markets. today erik schatzker spoke exclusively with mary jo white about the progress she has made thus far, and about other top priorities for the sec. i think we have accomplished a great deal already. one of my highest priorities confirmede i was was enhancing our equity market structure. we have taken a number of measures to date to do that. up the also set mechanism in the energy to do the first comprehensive review of the equity market structure in the agency's history. we have a market structure advisory committee

>> caller: i have substantial positions in both celgene and regeneron, purchased back about five years ago when you recommended them. with the recent threats on biopharmas by certain presidential candidates, both are down significantly from their highs. add to these holdings or should i be considering reductions? >> no. i have been saying, i wrote a piece for "real money" last night and articulated it today. i think the stocks have come down so much that it is too late to sell. is it too early to buy? i know it sounds like a copout, but i would say in some cases no. in some cases yes. the two you own, i would not be a seller. i'm more inclined to be a buyer. thank you for watching all these years. buyers are lurking underneath the current prices. the bid is real. we saw them in action today. on "mad money" tonight, we can't hide from reality that terrorism affects the economy. i'm going to take a closer look the at airline, cruise ship and online travel agencies. they were hit. and the brain behind taco bell and pizza hut has been on a tear this year. if yum! brands found the recipe fo

. >> we have sellgene, gilead, regeneron, am-gen and they are a better value. mary in georgia, mary. >> caller: jim, i appreciate you taking my call. >> of course. >> caller: assisting individual investors. >> of course. opinion about tide water. >> tide water had a major move. a really major move. today it was up big, up 12%. i cannot come on top of the 12% gain and tell you to buy it. it has to pull back. that move is based on oil going to 37, 38. regret that i said buy it so i'm not going to. sander in florida. >> caller: hey, jim. big boo-yah from the sunshine state. >> how are you? >> caller: doing great. how are you? >> good. i still believe in the long-term prospects of fitbit down 55%. again, listen, twitterati, i have been wrong. it's better to say i'm wrong than to say i'm early. i still believe. let's go to dave in illinois, dave. >> caller: dr. cramer. i like amicus therapeutics. now. when i see sell gene down, some of the other major ones like am-gen down i'm more excited. john in louisiana. >> caller: big boo-yah to you, jim. >> absolutely. >> cal

. >> losers are regeneron.s helps you lower your ldl, the so-called bad cholesterol element in your circulatory system. anyway a federal judge did uphold the validity of amgen's patent for the treatment. other two companies had competing treatment. that is what happened. liz: thank you, lori. three months into the year, look at the dow, has this hour erased losses for 2016 after a terrible start. is this rally the real deal? we'll have a portfolio manager putting $8 billion to work. patrick kaser, brandywine global cold dark days of january where the market plummeted are gone but do we see a swoon in june or july? we have referendum vote on the "brexit" in europe. and federal reserve meeting that could hike rates? >> absolutely. feels a lot better with the market up. i can hear you yes. can you hear me? liz: yes, go ahead. >> yeah, so it feels a lot better with the market up definitely, absolutely. this is much better place to be. i think one thing we're looking at is the fundamentals make the market look fairl

. >> did you buy regeneron. >> no wasn't me but i am already out of it. i'm shortening my name frame. >> still shortening the towel here or look for opportunity. >> i'm amazed when you think about 85% still above the short-term moving average which is incredible to have that much of the market that close to at least the year high and then you have the market that doesn't seem to want to play. the xlv is hanging in there a little bit better so they're having more of a rebound it's now sitting on 240 which was the february 11th low and i wouldn't be shocked if it did so i would just basically say maybe focus on the big pharma. these names are on the distribution and i think that the messages earnings growth does not automatically equal stock gains and the short squeeze elsewhere. it's a great example. >> there's money continuing to come out of the space and go into areas like the banks. the bank etf is up like five straight weeks. airlines are doing well. the transports are up nine weeks in a row. >> right. well, if you want to focus on banks for a second w

and some big biotech names like regeneron and alexion at lows. >> a news alert. we're talking about pershing square holdings, the publicly run fund entity run by bill ackman. s&p, credit ratings agency, placed pershing square holdings, again, the publicly traded company, they put their bbb rating, currently investment grade, on what they call credit watch negative. they say they have done this largely because of the precipitous decline in the market value of valeant pharmaceuticals which we know is one of the top holdings here. as a result, they say the debt to total assets ratio has increased. we're placing our bbb issue or credit rating on watch negative. they also say that it reflects the funds weak investment performance which resulted in higher leverage. we heard earlier they don't use, bill ackman in this particular unit, doesn't use margin type investing or margin type tools here. an interesting move here, credit ratings agency saying they're going to put it on credit watch negative. >> scott wapner had spoken to ackman directly and made clear that they di

regeneron analogs on hitting new lows as well. williams-sonoma, biggest sellouts. 6.5%. thursday "fbn:am" at 5:00 a.m. i will see you there. stuart: house speaker paul ryan moments ago said the presidential convention, the republican convention in cleveland is more likely to become open. right back, i believe he means that no candidate look at the 1237 delegates required for the nomination on the first ballot. that means it is open. paul ryan said that is now more likely. apple still fighting the fbi over encryption. general david petraeus on spn's new show wall street week on that subject. roll tape. >> if you ask me, do i want our government to have the ability to decrypt what someone has on our phone, i was a gas. do i want apple to make a back or to enable that? i would say no. i didn't like the ncaa director, i don't think admiral should be compelled to make it back door because they would make the entire technology so much more unsafe. stuart: there's a rough interpretation of that is general petraeus is on apple's side when it comes to encryption. judge napo